Key Takeaways
- The December 2024 UK‑US trade agreement commits the UK to raise medicine spending from 0.3 % to at least 0.6 % of GDP over the next ten years.
- In exchange, the United States will suspend threatened tariffs on British pharmaceutical exports and medical devices for three years.
- An analysis published in The British Medical Journal estimates the deal will add roughly £45 billion (≈ US $60 billion) to NHS medicine costs by 2036.
- If the extra spending is not covered by new government funds, the analysis projects 229,000 avoidable deaths in England, mainly from heart, respiratory, gastrointestinal, and cancer conditions, and warns that health inequalities could worsen.
- The authors argue that much of the additional expenditure will flow to multinational drug makers rather than staying in the NHS or the wider UK economy, and that by 2031 the deal’s costs could exceed the total annual value of UK pharmaceutical exports to the US.
- The UK government has heralded the agreement as a “landmark” deal that safeguards medicine access and stimulates investment, but the BMJ study challenges the assumption that avoiding US tariffs yields net economic benefits for Britain.
Overview of the US‑UK Trade Deal and Its NHS Implications
In December 2024 the United Kingdom and the United States reached a trade arrangement designed to avert punitive tariffs that President Donald Trump had threatened on certain British pharmaceutical imports. As part of the accord, the UK pledged to increase its national expenditure on new medicines from 0.3 % of gross domestic product (GDP) to a minimum of 0.6 % over the ensuing decade. In return, the United States agreed to forego imposing levies on UK exports of drugs and medical devices for the next three years. The deal was framed by both governments as a win‑win: protecting British patients’ access to medicines while shielding UK exporters from costly trade barriers.
Methodology and Findings of the BMJ Analysis
A peer‑reviewed study released in The British Medical Journal on Wednesday examined the fiscal and health consequences of the increased medicines spending commitment. Researchers from the University of York, the University of Liverpool, and Christchurch Hospital in New Zealand modelled the impact of diverting additional NHS funds toward higher‑priced pharmaceuticals under the assumption that no extra treasury money would be allocated to compensate for the rise. Their calculations indicate that the NHS will face an incremental cost of approximately £45 billion (about US $60 billion) by the end of 2036 to meet the 0.6 % GDP target for medicine spending.
How Extra Spending Translates into Avoidable Deaths
The authors emphasise that publicly financed health systems operate with fixed budgets; consequently, any increase in expenditure on one service line necessarily reduces resources available for others. Unless the UK government supplies supplementary financing, the reallocation of funds away from core NHS services—such as emergency care, mental health, preventive programmes, and chronic disease management—could precipitate 229,000 otherwise avoidable deaths in England by 2036. The projection stems from epidemiological models linking reduced access to essential services with higher mortality rates for cardiovascular, respiratory, gastrointestinal, and oncological conditions.
Distribution of the Projected Mortality Burden
The analysis anticipates that the bulk of the excess deaths will affect individuals suffering from heart disease, chronic obstructive pulmonary disease, other respiratory ailments, gastrointestinal disorders, and various cancers. These disease groups are particularly sensitive to interruptions in routine monitoring, medication adherence, and timely specialist interventions—areas that are likely to experience strain if NHS budgets are squeezed. Moreover, the study warns that existing health inequalities could widen, as disadvantaged populations tend to rely more heavily on publicly funded services and possess fewer private‑care alternatives.
Economic Flow: Where the Money Actually Goes
Critically, the researchers challenge the premise that the trade deal will generate net economic benefits for the UK. They note that the United Kingdom remains a net importer of medicines; therefore, a substantial portion of the additional £45 billion is likely to accrue to multinational pharmaceutical corporations rather than being retained within the NHS or the wider domestic economy. This outflow diminishes any potential fiscal stimulus from increased medicine spending and raises questions about the deal’s overall value for British taxpayers and patients.
Comparison with Pharmaceutical Export Values
Looking ahead, the BMJ paper estimates that by 2031 the cumulative cost imposed on the NHS by the higher medicines spending threshold will surpass the total annual value of UK pharmaceutical exports to the United States. At that point, the financial outflow associated with the deal would outweigh the revenue gained from selling British-made drugs and devices across the Atlantic, undermining the argument that the agreement protects or enhances the UK’s pharmaceutical trade balance.
Government Response and Official Stance
As of publication, the UK’s Department of Health and Social Care and the Department for Business and Trade had not issued an immediate reply to requests for comment on the BMJ findings. Prior to the analysis, officials had lauded the agreement as a “landmark” arrangement that would safeguard medicine access for patients and stimulate investment in the UK’s life‑sciences sector. The government’s narrative has centred on the avoidance of US tariffs as a protective measure for British exporters, while downplaying potential domestic fiscal pressures.
Critique of the Tariff‑Avoidance Assumption
The study’s authors directly contest the assumption that sidestepping threatened US tariffs translates into a net economic advantage for Britain. They argue that the avoidance of tariffs merely prevents a loss that would have been incurred on a relatively small segment of trade, whereas the compulsory rise in NHS medicine spending imposes a far larger, ongoing fiscal burden. Consequently, the purported benefits of the deal may be illusory, especially when weighed against the projected loss of life and strain on public health services.
Implications for Policy Makers
The findings urge policymakers to reconsider the trade‑off embedded in the US‑UK agreement. If the government wishes to honour the medicine‑spending pledge without jeopardising population health, it must either allocate new public funds specifically earmarked for pharmaceutical procurement of the NHS, or negotiate alternative concessions that reduce the financial impact on health services. Ignoring these fiscal realities risks turning a trade concession intended to protect exporters into a substantial public‑health cost, measured both in pounds spent and lives lost.